A top medical technology stock is trading at a big discount. Here's why I'm buying

Stryker is trading around $304 per share, roughly 23% below its 52-week high of $392.55 and below its historical 24–25x forward-earnings valuation, which contributor Sarat Sethi views as a buying opportunity. The company grew organic revenue about 10% annually over the past five years and adjusted EPS 12%–13% annually; it targets sales growth at the high end of its industry through 2028. Shares have faced pressure from an earlier cyberattack and an Inari supply disruption that hurt second-quarter 2026 growth, while potential government healthcare funding cuts remain a risk. Stryker announced Spencer Stiles will succeed Kevin Lobo as CEO next year.

Analysis

The bullish case hinges less on robotics optionality than on whether the recent operational interruptions prove recoverable without lasting share loss. If delayed shipments are mostly backlog, normalization can lift near-term growth and restore confidence; if hospitals substituted competing products or pushed procedures out, the “temporary” drag may not reverse cleanly. Mako also has a two-sided economics: placements can support recurring implant and instrument demand, but hospital capital constraints and surgeon adoption determine the pace of that annuity. Outpatient migration may support procedure volumes while shifting the customer mix and purchase economics.

The valuation argument is not self-validating: a discount to SYK’s own history may reflect lower expected growth, operational risk, or a compressed sector multiple rather than mispricing. The contributor’s disclosed ownership raises the bar for independent confirmation. The CEO handoff appears continuity-oriented, but execution on acquisition integration and margin expansion matters more than the appointment itself.

Near term, cyber remediation and Inari supply normalization are the key proof points. Over 1–3 months, watch organic growth, order/backlog conversion, and guidance; over 6–18 months, track Mako utilization and placements, margins, and procedure demand. The thesis fails if disruptions persist, guidance is cut, or procedure trends weaken enough to offset product growth.

Key Decisions for Investors

• Consider a staged long in SYK only after confirming the current price and that management’s next operating update shows improving shipment/service levels and backlog conversion. This preserves upside to a recovery and multiple normalization while limiting exposure to an unverified turnaround; do not anchor on the article’s quoted share price.
• Track organic growth, adjusted margin trajectory, and Mako placements/utilization against guidance. Improving operations with stable guidance supports adding; continued disruption or a growth/guidance downgrade is a signal to reduce or exit.
• Treat a valuation discount to historical multiples as a watch item, not a catalyst by itself. Compare forward earnings revisions and relative performance with major medtech peers; if estimates continue falling while the discount persists, the apparent cheapness is likely justified.